E
Eugene Braunwald
Researcher at Brigham and Women's Hospital
Publications - 1758
Citations - 278949
Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.
Papers
More filters
Journal Article
Indications for ACE inhibitors in the early treatment of acute myocardial infarction - Systematic overview of individual data from 100,000 patients in randomized trials
MariaGrazia Franzosi,Eugenio Santoro,Giulio Zuanetti,Colin Baigent,Rory Collins,M Flather,John Kjekshus,Roberto Latini,Lisheng Liu,Aldo P. Maggioni,Peter Sleight,Karl Swedberg,Gianni Tognoni,Salem Yusuf,Luigi Tavazzi,S Ball,Lars Køber,Christian Torp-Pedersen,Eugene Braunwald,Lemuel A. Moyé,Marc A. Pfeffer,Luigi Santoro,J Pogue,Yongfei Wang,Collaborat Aceimi. +24 more
TL;DR: These results support the use of ACE inhibitors early in the treatment of acute MI, either to a wide range of patients or selectively in patients with anterior MI and in those at increased risk of death.
Journal ArticleDOI
Clinical Significance of Mitral Regurgitation After Acute Myocardial Infarction
Gervasio A. Lamas,Gary F. Mitchell,Greg C. Flaker,Sidney C. Smith,Bernard J. Gersh,Lofty L. Basta,Lemuel A. Moyé,Eugene Braunwald,Marc A. Pfeffer +8 more
TL;DR: In this article, the authors analyzed left ventriculograms for diastolic and systolic volumes, global left ventricular sphericity, extent of wall motion abnormality, and endocardial curvature and found that the presence of MR was related to the risk of developing a cardiovascular event during 3.5 years of follow-up.
Journal ArticleDOI
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
Jessica L. Mega,Eugene Braunwald,Satishkumar Mohanavelu,Paul Burton,R Poulter,Frank Misselwitz,V Hricak,Elliot S. Barnathan,P Bordes,Adam Witkowski,V Markov,L Oppenheimer,Charles Michael Gibson +12 more
TL;DR: The use of an oral factor Xa inhibitor in patients stabilised after an acute coronary syndrome increases bleeding in a dose-dependent manner and might reduce major ischaemic outcomes.
Journal ArticleDOI
Heart Failure, Saxagliptin and Diabetes Mellitus: Observations from the SAVOR - TIMI 53 Randomized Trial
Benjamin M. Scirica,Eugene Braunwald,Itamar Raz,Matthew A. Cavender,David A. Morrow,Petr Jarolim,Jacob A. Udell,Ofri Mosenzon,KyungAh Im,Amarachi A. Umez-Eronini,Pia S. Pollack,Boaz Hirshberg,Robert Frederich,Basil S. Lewis,Darren K. McGuire,Jaime A. Davidson,Ph. Gabriel Steg,Ph. Gabriel Steg,Deepak L. Bhatt +18 more
TL;DR: In the context of balanced primary and secondary end points, saxagliptin treatment was associated with an increased risk or hospitalization for heart failure, and this increase in risk was highest among patients with elevated levels of natriuretic peptides, previousheart failure, or chronic kidney disease.
Journal ArticleDOI
Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes
Marc S. Sabatine,David A. Morrow,Robert P. Giugliano,Paul B.J. Burton,Sabina A. Murphy,Carolyn H. McCabe,C. Michael Gibson,Eugene Braunwald +7 more
TL;DR: Anemia is a powerful and independent predictor of major adverse cardiovascular events in patients across the spectrum of ACS.